The failure of PD‐1 inhibitors in MM immunotherapy may result from the deficiency of CD28 in activated CD8+ T cells as substantial evidences have demonstrated that successful reinvigoration of exhausted CD8+ T cells by PD‐1/PD‐L1 blockade is dependent on CD28.62, 63. Here, CD8A is linked to Miyoshi myopathy.